Suscribirse

Addictovigilance contribution during COVID-19 epidemic and lockdown in France - 20/08/20

Doi : 10.1016/j.therap.2020.06.006 
Maryse Lapeyre-Mestre a, , Alexandra Boucher b, Amélie Daveluy c, Valérie Gibaja d, Emilie Jouanjus a, Michel Mallaret e, Helene Peyrière f, Joëlle Micallef g

French Addictovigilance Network

Emilie Bouquet h, Leila Chaouachi i, Cécile Chevallier j, Sylvie Deheul k, Céline Eiden l, Nathalie Fouilhé m, Chistine Fournier-Choma n, Elisabeth Frauger o, Marylène Guerlais p, Reynald Le Boisselier q, Ghada Miremont r, Anne Roussin s, Juliana Tournebize t
h CEIP-A Poitiers, 86021 Poitiers, France 
i CEIP-A Paris, 75475 Paris, France 
j CEIP-A Lyon, 69424 Lyon, France 
k CEIP-A Lille, 59037 Lille, France 
l CEIP-A Montpellier, 34295 Montpellier, France 
m CEIP-A Grenoble, 38043 Grenoble, France 
n CEIP-A Clermont-Ferrand, 63003 Clermont-Ferrand, France 
o CEIP-A Marseille, 13385 Marseille, France 
p CEIP-A Nantes, 44093 Nantes, France 
q CEIP-A Caen, 14033 Caen, France 
r CEIP-A Bordeaux, 33076 Bordeaux, France 
s CEIP-A Toulouse, 31000 Toulouse, France 
t CEIP-A Nancy, 54035 Nancy, France 

a CEIP-A Toulouse, 31000 Toulouse, France 
b CEIP-A Lyon, 69424 Lyon, France 
c CEIP-A Bordeaux, 33076 Bordeaux, France 
d CEIP-A Nancy, 54035 Nancy, France 
e CEIP-A Grenoble, 38043 Grenoble, France 
f CEIP-A Montpellier, 34295 Montpellier, France 
g CEIP-A Marseille, 13385 Marseille, France 

Corresponding author. CEIP-addictovigilance de Toulouse, service de pharmacologie médicale et clinique, CHU et université de Toulouse, 37, allées Jules-Guesde, 31000 Toulouse, France.CEIP-addictovigilance de Toulouse, service de pharmacologie médicale et clinique, CHU et université de Toulouse37, allées Jules-GuesdeToulouse31000France

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

Summary

Addictovigilance is a safety monitoring targeted at substances with potential for abuse and dependence. This vigilance was involved during the period of COVID-19 epidemic due to the significant changes in access to drugs and psychological disruption caused by the pandemic and lockdown. This article aims to present the different steps implemented by the French Addictovigilance network in collaboration with the French Health authorities from March to May 2020, including monitoring of potential harmful events, and scientific communication. The first events were identified through the continuity of the networking between the French addictovigilance centres and their partners: community pharmacies, general practitioners, specialized structures and emergency wards. As soon as the lockdown began, first cases of overdoses (lethal or not) were reported with opioids, mainly with methadone, and other opioids (heroin, oxycodone, tramadol or antitussive codeine). Lockdown-related noteworthy events consisted in clinical cases or other relevant information for which lockdown clearly played an important role: among the many substances identified at least once, pregabalin, benzodiazepines, cannabis, cocaine and nitrous oxide were the most significant in terms of prevalence, seriousness or particularly specific to the lockdown context. Despite significant decrease in the activity and travel limited to vital needs, community pharmacies continued to identify falsified prescriptions in this period, highlighting an increase in suspicious requests for pregabalin, codeine and tramadol. In parallel, the French addictovigilance network continued its communications efforts in the period, issuing a newsletter on tramadol, a press release on methadone and naloxone, and participating in the COVID-19 frequently asked questions (FAQs) of the French Society of Pharmacology and Therapeutic website (covid19). COVID-19 epidemic has been an important challenge for addictovigilance, and has proved that this monitoring is highly essential for alerting health professionals and health authorities to points of vigilance in the field of psychoactive substances.

El texto completo de este artículo está disponible en PDF.

Keywords : Addictovigilance, COVID-19, Lockdown, Abuse, Addiction, Psychoactive substances, Methadone, Pregabalin, Cocaine, Nitrous oxide


Esquema


© 2020  Société française de pharmacologie et de thérapeutique. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 75 - N° 4

P. 343-354 - juillet 2020 Regresar al número
Artículo precedente Artículo precedente
  • Challenges of autoimmune rheumatic disease treatment during the COVID-19 pandemic: A review
  • Lucile Grange, Philippe Guilpain, Marie-Elise Truchetet, Jean-Luc Cracowski, French Society of Pharmacology and Therapeutics
| Artículo siguiente Artículo siguiente
  • Non-steroidal anti-inflammatory drugs, pharmacology, and COVID-19 infection
  • Joëlle Micallef, Thomas Soeiro, Annie-Pierre Jonville-Béra, French Society of Pharmacology, Therapeutics (SFPT)

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2024 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.